Supplier log in
Future Procurement Opportunity (FPO) - Supply of infliximab, rituximab, and tocilizumab to Health New Zealand hospitals
Details
| RFx ID : | 33372832 |
| Tender Name : | Future Procurement Opportunity (FPO) - Supply of infliximab, rituximab, and tocilizumab to Health New Zealand hospitals |
| Reference # : | A1972894 |
| Open Date : | Q1 2026 |
| Indicative RFx Release Date : | Q1 2026 [?] |
| Tender Type : | Future Procurement Opportunity (FPO) |
| Project Status : | Initial development [?] |
| Indicative Total Value : | $100M + [?] |
| Tender Coverage : | Sole Agency [?] |
| Categories : |
|
| Regions: |
|
| Required Pre-qualifications : | None |
| Contact : |
Pharmac Procurement Team procurement@pharmac.govt.nz . |
Pharmac is planning on issuing a competitive process for the supply of infliximab, rituximab, and tocilizumab to Health New Zealand hospitals.
This competitive process may result in the maintenance of current access, or the widening of access to any of the three biologics included in the process.
Pharmac would reserve the right to widen access to any or none of the three biologics included in a competitive process subject to budget availability.
The approximate gross expenditure of infliximab, rituximab, and tocilizumab in the 2024/25 FYR was $42 million, $20 million, and $6 million respectively. Confidential rebates currently apply to all three chemicals, which reduces the net expenditure paid by Pharmac.
For current funding restrictions, please view the Pharmaceutical Schedule at https://schedule.pharmac.govt.nz/HMLOnline.php
